Year: 2025

Calendar Fourth Quarter Results In-Line with Previously Announced Expectations Reaffirmed Outlook on Transformative Electric Arc Furnace (EAF) Project, Including First Arc in April SAULT STE. MARIE, Ontario, March 12, 2025 (GLOBE NEWSWIRE) — Algoma Steel Group Inc. (NASDAQ: ASTL; TSX: ASTL) (“Algoma” or “the Company”), a leading Canadian producer of hot and cold rolled steel sheet and plate products, today announced results for the three and nine month periods ended December 31, 2024. As previously reported, the Company has changed its fiscal year end from March 31 to December 31, resulting in a transitional nine month fiscal reporting period ending December 31, 2024. Unless otherwise specified, all amounts are in Canadian dollars. Business Highlights and Calendar 2024 to Calendar 2023 Fourth Quarter ComparisonsConsolidated...

Top Line Growth Set to Continue; Improving Outlook for 2025 NORTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) — CPS Technologies Corporation (NASDAQ:CPSH) (“CPS” or the “Company”) today announced financial results for the fiscal fourth quarter ended December 28, 2024. Fourth Quarter SummaryRevenue of $5.9 million for the fourth quarter of 2024 versus $6.7 million in the prior-year period, reflecting the previously-announced fulfillment of the Company’s HybridTech Armor® contract with Kinetic Protection for the U.S. Navy; revenue rose significantly relative to the third quarter of 2024, due to higher production rates and associated customer shipments. In addition, fourth quarter revenue was slightly higher than first quarter revenue, demonstrating that the Company has fully replaced its armor contract with revenue from other products.After...

Total Backlog Climbs to Record $37.2 Million; 70% Gross Margins; Cash Burn Declines TORONTO, March 12, 2025 (GLOBE NEWSWIRE) — Xtract One Technologies Inc. (TSX: XTRA) (OTCQX: XTRAF) (FRA: 0PL) (“Xtract One” or the “Company”) a leading technology-driven threat detection and security solution that prioritizes the patron access experience by leveraging AI, today announced fiscal second quarter results for the three months ended January 31, 2025. All information is in Canadian dollars unless otherwise indicated. Second Quarter HighlightsQuarterly revenue of $3.4 million for the three months ended January 31, 2025 versus $2.9 million in the prior-year period. Gross margin of 70% for the second quarter of fiscal 2025 versus 61% in the prior-year period. Total contract value of new bookings1 was $13.5 million for the three months ending...

Fourth Quarter and Full Year 2024 Highlights:Gross revenues of $111.1 million for the year, up 1% versus 2023 Operating income of $32.2 million for the year, down 1% versus 2023 Operating profit margin of 29.9% for the year, versus 30.6% for 2023 Net income of $27.4 million for 2024, down 1% versus 2023, and GAAP diluted EPS of $2.26 versus $2.28 for 2023 Total cash returned to shareholders during 2024 of $29.5 million, comprised of dividends of $26.6 million and repurchases of common shares of $2.9 million, down 1% versus 2023 Announcing first quarter 2025 dividend of $0.18 per share 567 OTCQX® and 1,050 OTCQB® companies at year end 43 graduates to a national securities exchange during 2024 114 subscribers to OTC Link ECN as of year-end 2024, up 6 versus 2023 141 unique OTC Link subscribers, up 5 versus 2023 Approximately 38,000 average...

The Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in Q3 of 2025. Four presentations for SCY-247 were accepted by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) congress, April 11-15, 2025 in Vienna, Austria. SCYNEXIS continues to make progress towards the restart of the Phase 3 MARIO study in invasive candidiasis. The Company anticipates the restart, pending the FDA’s lifting of the clinical hold, in the second quarter of 2025. SCYNEXIS ended 2024 with cash, cash equivalents and investments of $75.1 million, and projects a cash runway into Q3 2026.JERSEY CITY, N.J., March 12, 2025 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome...